Viatris (VTRS) Non-Current Debt (2019 - 2026)
Viatris (VTRS) posted Non-Current Debt of $11.6 billion for Q2 2026, down 6.45% on a QoQ basis from $12.4 billion in Q1 2026, and down 9.22% year-over-year from $12.8 billion in Q2 2025.
Analysis
Viatris (VTRS) Non-Current Debt (2019 - 2026) Analysis & Trends
Viatris has reported Non-Current Debt for 8 years, with the latest figure at $11.6 billion in Q2 2026.
- On a quarterly basis, Non-Current Debt fell 9.22% year-over-year to $11.6 billion in Q2 2026; TTM through Jun 2026 was $11.6 billion, a 9.22% decrease from a year earlier, with the FY2025 full-year figure at $12.5 billion, down 11.1% from the prior year.
- Non-Current Debt was $11.6 billion for Q2 2026 at Viatris, down from $12.4 billion in the prior quarter.
- The five-year high for Non-Current Debt was $19.2 billion in Q2 2022, with the low at $11.6 billion in Q2 2026.
- Average Non-Current Debt over 5 years is $15.5 billion, with a median of $15.4 billion recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Non-Current Debt declined 3.69% in 2023, then retreated 16.24% in 2024.
- Over 5 years, Non-Current Debt stood at $18.0 billion in 2022, then retreated by 10.14% to $16.2 billion in 2023, then declined by 13.28% to $14.0 billion in 2024, then fell by 11.1% to $12.5 billion in 2025, then decreased by 6.96% to $11.6 billion in 2026.
- The last three Non-Current Debt figures came in at $11.6 billion (Q2 2026), $12.4 billion (Q1 2026), and $12.5 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | 12.09 Bn |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn | 11.61 Bn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 150.67 Mn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn | 2.57 Bn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 20.74 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | 1.26 Bn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 280.16 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 609.56 Mn |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.61 Bn |
| Mar 31, 2026 | 12.41 Bn |
| Dec 31, 2025 | 12.48 Bn |
| Sep 30, 2025 | 12.49 Bn |
| Jun 30, 2025 | 12.79 Bn |
| Mar 31, 2025 | 14.18 Bn |
| Dec 31, 2024 | 14.04 Bn |
| Sep 30, 2024 | 14.30 Bn |
| Jun 30, 2024 | 14.73 Bn |
| Mar 31, 2024 | 16.07 Bn |
| Dec 31, 2023 | 16.19 Bn |
| Sep 30, 2023 | 17.08 Bn |
| Jun 30, 2023 | 17.25 Bn |
| Mar 31, 2023 | 18.07 Bn |
| Dec 31, 2022 | 18.02 Bn |
| Sep 30, 2022 | 18.72 Bn |
| Jun 30, 2022 | 19.21 Bn |
| Mar 31, 2022 | 18.76 Bn |
| Dec 31, 2021 | 19.72 Bn |
| Sep 30, 2021 | 19.85 Bn |